A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This phase II clinical study is designed to evaluate the 1 year local tumor control rates
after the targeted therapy of intensity-modulated radiation therapy synchronized chemotherapy
with nimotuzumab combined with S-1 in local advanced esophageal squamous cell carcinomas
based on Nutritional Risk Screening NRS2002.